Long-Acting Injectable Antipsychotic Medications in an Aging Population-View Recorded Webinar

Video Transcription

Video Summary

In the video, Dr. Megan Arant discusses the use of long-acting injectable antipsychotic medications in an aging population. She explains that SMI Advisor, a resource for evidence-based care for serious mental illness, is dedicated to helping clinicians implement evidence-based care for those living with serious mental illness. Dr. Arant emphasizes the importance of utilizing these medications to ensure consistent and stable plasma concentrations of the drug, reducing relapse and hospitalization rates. She discusses the limited amount of literature available on the use of long-acting injectables in the elderly population and highlights the need for more research in this area. Dr. Arant also addresses the various pharmacokinetic and pharmacodynamic changes that occur in the aging population, including decreased gastric motility, decreased renal function, and changes in neurotransmitter receptors. She emphasizes the importance of individualizing treatment plans and monitoring for adverse effects such as movement disorders and metabolic syndrome. Additionally, Dr. Arant discusses the challenges of medication adherence in the elderly population and the potential benefits of long-acting injectables in improving adherence. She also provides recommendations for injection administration, including considerations for injection volume, injection site, and injection technique. Finally, Dr. Arant acknowledges the challenges and regulations surrounding the use of antipsychotics in the elderly and the importance of accurate diagnosis and documentation in these cases.

Keywords

long-acting injectable antipsychotic medications

aging population

evidence-based care

serious mental illness

plasma concentrations

pharmacokinetic changes

pharmacodynamic changes

medication adherence

injection administration

challenges